Publications by authors named "A Krupa"
Anhedonia constitutes a core symptom of major depressive disorder (MDD) mediating the ultimate goal of MDD treatment: functional remission. Anhedonia is also present in other clinical populations, including patients with chronic pain. Recent data links anhedonia to insulin resistance (IR).
View Article and Find Full Text PDFArticle Synopsis
- The study developed a method to create clindamycin-modified polymer-ceramic hybrid coatings that may help prevent surgical site infections during bone therapy through controlled drug delivery.* -
- The coatings were tested for their ability to absorb liquids and release the drug effectively, with results showing that those with higher absorption capacity released clindamycin faster.* -
- Further tests confirmed that the coatings are not toxic to mouse and human bone cells, suggesting their potential as safe drug carriers in bone regenerative applications.*
Background: We have previously demonstrated that dietary saturated fatty acids (SFA), when compared to polyunsaturated fatty acids (PUFA), are preferentially partitioned into oxidation pathways. However, it remains unclear if this preferential handling is maintained when hepatocellular metabolism is shifted toward fatty acid (FA) esterification and away from oxidation, such as when hepatic de novo lipogenesis (DNL) is upregulated.
Aim: To investigate whether an acute upregulation of hepatic DNL influences dietary FA partitioning into oxidation pathways.
Trazodone is a serotonin antagonist/reuptake inhibitor, approved for treating major depressive disorder (MDD). Oral formulations are widely studied and marketed in several countries worldwide while there is little evidence to support use of parenteral formulation. Our narrative review summarizes pharmacological properties and clinical data concerning use of parenteral trazodone in mood disorders.
View Article and Find Full Text PDF